While the coronavirus has impacted millions of Americans across the United States, it has hit the elderly population particularly hard. In fact, more than 40 percent of coronavirus deaths in the U.S. have been linked to long-term care facilities, according to a New York Times survey. In an effort to bring those numbers down, pharmaceutical company Eli Lilly, in partnership with the National Institutes of Health (NIH), has just launched a late-stage antibody treatment trial focusing on residents and staff at nursing homes.
"COVID-19 has had a devastating impact on nursing home residents," Lilly's chief scientific officer Daniel Skovronsky said in a statement. "We're working as fast as we can to create medicines that might stop the spread of the virus to these vulnerable individuals."
The trial is expected to enroll up to 2,400 participants who live or work at a facility and have recently been diagnosed with the disease. The trial will evaluate the safety and success of using LY-CoV555, a potent, neutralizing antibody that works against the spike protein of the novel coronavirus. The trial will look at whether a single dose of the antibody treatment reduces the rate of infection over four weeks as well as symptoms over eight weeks.
"The importance of these kinds of therapies for people like the elderly or immunocompromised is that they can provide the hope and the safety net that these people really need right now," said Andrew Adams, vice president of new therapeutic modalities & COVID-19 research at Eli Lilly, who is overseeing the trial. "I think people in those populations are really desperate and looking for something to help with the coronavirus."
Eli Lilly is taking its trial on the road with customized mobile research units that can travel directly to areas that are experiencing outbreaks.
"This is an interesting solution, to bring the medicine to these vulnerable patients," said Adams. "This lets us be flexible and move these trials around the country, tracking these trials as we come across them."
Adams said he is hoping Eli Lilly will have results on the efficacy of these antibodies in the fourth quarter of this year. Even if successful, though, he says research for a vaccine needs to continue.
"These have to be thought of as more of a bridge, where a vaccine provides long-term protection in terms of years of immunity, where we will provide hopefully in the range of months with these types of treatments. We hope this to be a short-term bridge to the long-term effective vaccination," he said.
On this episode of Cheddar Innovates: President of The Pillow Bar breaks down how everyone can benefit from a pillow customized to their unique way of sleeping; CEO of H2Pro explains how to bring environmentally friendly hydrogen to scale; Cheddar gets a look at Curiosity Stream's 'Suppressed Science.'
On this episode of Cheddar Innovates: Gardenuity CEO breaks down how gardening can improve your wellbeing; Augmedix CEO discusses how this technology is helping doctors fight burnout; Cheddar gets a look at Curiosity Stream's 'Suppressed Science.'
On this episode of Cheddar Innovates: Atom Limbs CEO breaks down how the Atom Touch prosthetic is different from other prosthetics on the market; CEO & Chief Scientific Officer of MyMD explains how the MYMD-1 is on track to be the first FDA-approved drug to treat aging and age-related diseases; A look at Curiosity Stream's 'The Future of Warfare.'
On this episode of Cheddar Innovates: SkilsVR CEO explains how virtual reality is being used to train frontline workers to handle difficult customers; Rubicon CEO breaks down how technology and sustainability will go hand in hand in the future; Cheddar gets a look at 'Our Infinite Universe.'
A UN report is warning that relying on seawalls and other engineering fixes will not be enough to keep communities safe from rising sea levels and climate change consequences. Dr. Steve Rose, a senior research economist at the Electric Power Research Institute, joins Cheddar News to discuss.
As gas prices surge amid the Russian invasion of Ukraine, other nations could potentially transition faster to using clean energy than previously expected. Philip K. Verleger, a senior fellow at the Niskanen Center, joined Cheddar News to explain how this could be a possibility in the near future. "Part of the reason I think we have this invasion and the tantrum that's being thrown by Russia, terrible tantrum, is because the Russians were trying to slow down the transition," he said. "Ironically they speeded it up."
As Russia intensifies its war on Ukraine, President Biden announced a ban on oil imported from the aggressor nation. Critics of Russia have said this would be the best way to force Putin to pull back, but curbs on Russian oil exports are expected to send already skyrocketing oil and gas prices even higher, further impacting consumers, businesses, financial markets, and the global economy. Leslie Beyer, CEO of the Energy Workforce and Technology Council, joined Cheddar News' Closing Bell to discuss. "It's certainly going to increase pricing, but it is the right thing to do," she said. "The industry itself has already pulled out of the significant portion of its operations in Russia."
On this episode of Cheddar Innovates: Vision Marine Technologies CEO discusses how e-boats will play a role in the fight against the climate crisis; Lasso CEO breaks down how the design behind these compression socks can prevent injuries and improve performance; Cheddar gets a look at Curiosity Stream's 'The Tombs Of Egypt.'
Vaccine maker Pfizer delayed its COVID shot for kids allegedly due to a lack of data on how it would perform against the omnicron variant, according to the Wall Street Journa. Peter Pitts, professor and founder of the Center for Medicine in the Public Interest and a former FDA associate commissioner, joined Cheddar News Wrap to break down why the authorization can't be rushed. "Going forward, the FDA wants to look at data specifically against omicron, and it looks like that's going to be a three-shot regimen versus two, which was efficient against delta but not omicron because obviously omicron is more infectious," said Pitts.
Walker Ross, Assistant Professor of Sports Business Management at Florida Southern College, joins Business of Sports: The Beijing Winter Olympics 2022, where he says that actions Beijing and other Olympic host sites have been implementing to combat climate change has simply not been enough to offset their carbon footprint.
